DBV Technologies
2002
FOUNDED
PUBLIC
STATUS
301-400
EMPLOYEES
DBV
STOCK SYMBOL
$15.63
SHARE PRICE
(As of Tuesday Closing)
Description
DBV Technologies SA is a biotechnology company that provides therapy for food and pediatric allergy patients. The company focuses on discovering, developing, manufacturing, and commercializing treatments for severe allergies in the United States and other global markets. DBV's method of delivering biologically active compounds to the immune system is through self-administered and noninvasive products. The company also explores potential applications of its platform in vaccines and other immune diseases.
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
PAR
Primary Office
- 177-181 Avenue Pierre Brossolette
- 92120 Montrouge
- France
+33 01 00 00 00 00
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore DBV Technologies’s full profile, request a free trial.
DBV Technologies Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $8.64 - $32.28 | $735M | $15.63 | -$6.35 | 234K | 47M |
DBV Technologies Financials Summary
|
In Thousands,
USD |
TTM
30-Jun-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 469,146 | 135,824 | 1,027,095 | 1,381,975 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (190,378) | (192,787) | (160,208) | (126,853) |
| Net Income | (198,266) | (195,981) | (166,563) | (126,688) |
| Total Assets | 212,234 | 196,464 | 213,315 | 302,364 |
| Total Debt | 29,306 | 2,836 | 4,979 | 4,880 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
DBV Technologies Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore DBV Technologies‘s full profile, request access.
Request full access to PitchBookDBV Technologies Competitors (19)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics | Corporate Backed or Acquired | Brisbane, CA | 000 | 00000 | 00000000000 | 00000 |
| 000000 | Venture Capital-Backed | San Diego, CA | 0 | 00.000 | 0000000000 0 | 00.000 |
| 000000 | Formerly VC-backed | Lyon, France | 000 | 000.00 | 00000000 | 000.00 |
| 0000000 | Formerly VC-backed | Summit, NJ | 0000 | 000.00 | 000000&0 | 000.00 |
| 000000000 00000000 | Venture Capital-Backed | Rockville, MD | 00 | 000.00 | 0000000000 0 | 000.00 |
DBV Technologies Executive Team (17)
3 Former Executives
You’re viewing 5 of 17 executives. Get the full list »DBV Technologies Board Members (11)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Daniel Soland | Self | Board Member | 000 0000 | |
| Maïlys Ferrère | Self | Board Member | 000 0000 | |
| Michael Goller | DBV Technologies | Board Member | 000 0000 | |
| Michel De Rosen | DBV Technologies | Chairman & Board Member | 000 0000 | |
| Torbjörn Bjerke MD | Self | Board Member | 000 0000 |
6 Former Board Members
You’re viewing 5 of 11 board members. Get the full list »